Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVAX-008 in Chronic Hepatitis B
NCT07179653Phase 2Active, not recruiting
- Sponsor
- Grand Theravac Life Science (Nanjing) Co., Ltd.
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing TVAX-008 with Placebo (2 arms). Primary endpoint: HBsAg clearance rate at Week 49. Started Jan 2025; status: active, not recruiting.
02
Drugs
TVAX-008
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07179653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07179653.